738577-08-7

Basic information

• Product Name: 4-Ethynylpiperidine
• Synonyms: 4-Ethynylpiperidine;Piperidine, 4-ethynyl-
• CAS NO: 738577-08-7
• Molecular Formula: C₇H₁₁N
• Molecular Weight: 109.16894
• Mol File: 738577-08-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 143.8 °C at 760 mmHg
• Flash Point: 32.9 °C
• Appearance: /
• Density: 0.91 g/cm³
• Vapor Pressure: 5.25mmHg at 25°C
• Refractive Index: 1.481
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4-Ethynylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Ethynylpiperidine(738577-08-7)
• EPA Substance Registry System: 4-Ethynylpiperidine(738577-08-7)

Safety Data

• Hazardous Substances Data: 738577-08-7(Hazardous Substances Data)

Usage

General Description

4-Ethynylpiperidine is a chemical compound with the formula C7H11N. It is a derivative of piperidine, and its structure includes a five-membered ring with a triple bond attached to one of the carbons. 4-Ethynylpiperidine is commonly used in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is also known for its potential as a ligand in metal-catalyzed reactions. 4-Ethynylpiperidine is considered to be a useful building block in organic chemistry due to its versatile reactivity and ability to participate in various types of chemical reactions. It is an important intermediate in the production of various commercial chemical products.

InChI:InChI=1/C7H11N/c1-2-7-3-5-8-6-4-7/h1,7-8H,3-6H2

Upstream product

• 287192-97-6 4-ethynyl-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 732242-82-9 2-amino-1-(4-ethynyl-piperidin-1-yl)-ethanone 
• 1394372-86-1 (3R,3aR,6R,6aR)-6-((6-chloro-5-(4-(piperidin-4-ylethynyl)phenyl)-1H-imidazo[4,5-b]pyridin-2-yl)oxy)hexahydrofuro[3,2-b]furan-3-ol 
• 515846-46-5 (R)-3-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid allyl ester 
• 515846-55-6 (R)-4-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid methyl ester 
• 515846-42-1 (R)-5-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]furan-2-carboxylic acid 
• 515846-59-0 (R)-4-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid 

Relevant articles and documents

TARGETED BIFUNCTIONAL DEGRADERS

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

Design and synthesis of novel triazolo-lapatinib hybrids as inhibitors of breast cancer cells

A series of triazolo-lapatinib hybrids were synthesized via copper (II)-oxide nanoparticle (Cu2O-NP)-catalyzed azide-alkyne cycloaddition. The ability of these compounds to reduce the viability of breast cancer SKBR3 and SUM159 cells and stem cell-like KG-1a leukemia cells was subsequently evaluated. Compared with lapatinib, compounds 6c–f were more potent than lapatinib against the three cell lines. Next, the toxicity of compounds 6c–f was assessed in zebrafish. Compound 6d had comparable toxicity with lapatinib at 200 μM (mortality rate = 10 vs. 10%), and compound 6e had lower toxicity than lapatinib at 200 μM (mortality rate = 0 vs. 10%). Thus, compound 6e is a promising lead compound worthy of further investigation. [Figure not available: see fulltext.].

Discovery of a potent small molecule IL-2 inhibitor through fragment assembly

Using a site-directed fragment discovery method called tethering, we have identified a 60 nM small molecule antagonist of a cytokine/receptor interaction (IL-2/IL2Rα) with cell-based activity. Starting with a low micromolar hit, we employed a combination